FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Astellas Granted Orphan Status for Antifungal

[ Price : $8.95]

FDA grants Astellas an orphan drug designation for isavuconazole and its use in treating invasive candidiasis.

FDA Accepts Boehringer NDA for Spiriva Respimat for Asthma

[ Price : $8.95]

FDA accepts for review a Boehringer Ingelheim NDA for Spiriva Respimat (tiotropium bromide) inhalation spray that is seeking an in...

Woodcock Discusses Collaborations to Advance Drug Development Science

[ Price : $8.95]

CDER director Janet Woodcock discusses collaborative efforts to advance regulatory science.

Amgen Asks for Biosimilar Submission Alerts to Innovators

[ Price : $8.95]

Amgen petitions FDA to require biosimilar applications to include a certification by the applicant that they will provide the refe...

FDA Nixes Data Fraud Rumors on Sarepta NDA Delay

[ Price : $8.95]

In an unprecedented move, FDA issues a statement to clarify that data integrity or fraud is not at the center of why Sarepta Thera...

OIG Work Plan Targets Five FDA Drug Program Areas

[ Price : $8.95]

The HHS Office of the Inspector General announces its Work Plan for fiscal year 2015 that targets five FDA drug program areas.

Lannett Gains Approval for Generic Femara

[ Price : $8.95]

FDA approves a Lannett Co. ANDA for letrozole tablets USP, 2.5 mg, a generic copy of Novartis Femara tablets.

FDA Panel Backs Daiichi Sankyo Stroke Drug

[ Price : $8.95]

FDAs Cardiovascular and Renal Drugs Advisory Committee recommends approval of Daiichi Sankyos once-daily Savaysa (edoxaban) 60 mg ...

Info on Commissioners Fellowship Program Sent to OMB

[ Price : $8.95]

Federal Register Notice: FDA submits a proposed collection of information to the Office of Management and Budget on the FDA commis...

FDA Corrects Notice on Recordkeeping for Exports

[ Price : $8.95]

Federal Register Notice: FDA corrects a notice on exports and notification and recordkeeping requirements.